AAM Buy American Fact Sheet
A diverse, resilient supply chain for prescription medicine will moderate the risk of drug shortages and ensure patient access during the COVID-19 pandemic and beyond.
AAM Interim CEO Jeff Francer on COVID-19
First in a series, view second.
AAM Statement on 2019 FDA Drug Shortages Task Force Report
WASHINGTON DC (October 29, 2019) – AAM applauds FDA for recognizing the multi-faceted challenges that can lead to drug shortages. In particular, deteriorating market conditions have led to sustainability issues in the manufacture of certain medicines. AAM and its members commit to working with FDA and policymakers to advocate for policies to ensure a healthy, sustainable market for safe, effective and affordable medicines for patients.
Generic Prescription Drug Shortage Bills
AAM’s core mission is to improve patients’ lives by advancing timely access to affordable, FDA-approved generic and biosimilar medicines. AAM is the nation’s leading trade association for manufacturers and distributors of generic and biosimilar prescription medicines. Our members provide more than 36,000 jobs at nearly 150 facilities, and manufacture more than 61 billion doses of prescription medicine in the US annually.
Key Points:
Preliminary Recommendations for Addressing Drug Shortages
Generic and Biosimilars Approvals Are Only Half the Story
The U.S. Food and Drug Administration (FDA) plays a critical role in keeping Americans healthy. When it comes to drug approvals, the FDA’s scientists and regulators strive every day to keep pace with the most current advances in science so that patients can benefit from innovative, safe, and effective medicines.
FDA Approvals: Good News for Patients, More Work to Do (Part 2)
Continued from Part 1...
We greatly appreciate the FDA’s efforts to increase the number of generic drug approvals and take action on applications in the backlog.
What some people also might not understand is that not all generic medicines approved by the FDA make it to market.
White Paper: Ensuring the Future of Accessible Medicines in the U.S.
WASHINGTON, D.C. (February 12, 2018) In its newest white paper, released today, the Association for Accessible Medicines (AAM) finds that generics and biosimilars continue to provide savings for patients, but that uninterrupted patient access to these affordable prescription medicines is at risk.
AAM White Paper: Ensuring the Future of Accessible Medicines in the U.S.
Patient health and well-being depends on the uninterrupted availability of lower-cost generic and biosimilar medicines. Moreover, as patients live longer the importance of a robust and sustainable generic and biosimilar medicines industry becomes only that much more important. Policymakers must act quickly to ensure continued saving and market-based competition, as well as prevent shortages, for future availability of affordable medicines. This requires: